Sareum narrows losses
21st Feb 2011 15:56
Sareum, the cancer drug discovery business that earlier this month shot up after announcing positive results from a leukaemia study, narrowed losses in the half year to 31 December. Pre-tax losses narrowed to £281,000 from £321,000 over the same period a year ago. "Recent fundraisings provide us w
Read moreSmall caps round-up: Henry Boot, Firestone Diamonds, Amino Tech...
7th Feb 2011 11:52
Property developer Henry Boot says it will move to a net cash position after it agreed the sale of a shopping centre in Ayr for £33.8m and the sale of land with planning permission to build houses in Buckingham for an undisclosed fee. Henry Boot said last month that one of its goals is to 'manage d
Read moreSmall caps round-up: Amphion, Bioquell, Ablon...
16th Mar 2010 10:50
Shares in Amphion Innovations jumped after the medical and technology sector said it was cautious but confident in the strength of its model following a year which saw revenue increase to $8.6m from $7.1m in 2008, but losses increase to $2.9m from $1.8m. Shares in Bioquell moved in the other direct
Read moreSmall caps round-up: ING Real, Intellego, Oxford Intruments...
20th Jan 2010 13:10
ING UK Real Estate Income Trust will repay £15m of debt through the purchase and cancellation of loan notes at a discount to nominal value in two separate transactions. The transaction will result in a one off gain to NAV expected to be in the order of £680,000, and will also save over £719,000 per
Read moreSmall caps round-up: Ariana, Gemfields, Sareum
27th Oct 2009 11:09
Turkey-focused gold miner Ariana Resources has set up a 50:50 joint venture to combine its two main projects, Sindirgi and Tavsan, into a single conceptual entity. The company confirmed its partner in the 'Red Rabbit' project as Turkish turn-key construction firm Proccea Construction. "A Memorandu
Read moreSmall caps round-up: ProStrakan, Sareum,Sirius
6th Oct 2009 09:47
Speciality pharmaceutical company ProStrakan's New Drug Application (NDA) filing for Abstral has been accepted for review by the US Food and Drug Administration (FDA). Subject to successful completion of the US approval process, the Scottish firm plans to launch Abstral, which helps ease pain for
Read more